Shelley V. Ching, DVM, Ph.D., DACVP
Shelley Ching has over 25 years of experience in regulatory toxicology/risk assessment, nonclinical development of pharmaceuticals, and toxicologic pathology. Shelley received her veterinary degree from the University of Georgia in 1980 and Ph.D. in veterinary pathology from Colorado State University in 1988. She is board certified by the American College of Veterinary Pathologists. For the past 17 years as President of SVC Associates, Inc., she has been a consultant to a number of pharmaceutical companies and research organizations to provide nonclinical toxicology and pathology drug development strategies and management for compounds intended for many different therapeutic indications.
Shelley has served on several scientific and development advisory boards for pharmaceutical companies and is on the Scientific Advisory Board for the Consortium for Parasitic Drug Development at the University of North Carolina for the Bill and Melinda Gates Foundation. Prior to becoming a consultant, she was employed by Glaxo Wellcome, Inc. where she had international responsibility for the nonclinical strategy, management, development and safety assessment of compounds in full development in a wide range of therapeutic areas. Prior to her position at GW, she was at Merck Research Laboratories and Burroughs Wellcome, Co. where she was study pathologist and toxicology study director on a number of rodent and non-rodent studies. Shelley also participated on international project teams in the development of antiviral, neurological, pulmonary and metabolic drug products. At Burroughs Wellcome, she managed the pathology and toxicology groups. Shelley was Principal Investigator for a NTP Pathology Support Program at Integrated Laboratory Systems where she managed pathology research studies and served as chairperson for NTP Pathology Working Groups. Prior to her experience in industry, she was a Research Assistant Professor in the Department of Pathology at the University of Miami School of Medicine where she was responsible for a research program in metabolic and bone disease and for service support in diagnostic pathology.
Shelley has served on the Membership Committee (2006-2009) of the American College of Toxicology and is also a member of the Society of Toxicology, the NC Society of Toxicology, and Society of Toxicologic Pathologists. She has published and presented on the toxicology and pathology of bone disease, ophthalmology, antiviral and pulmonary drug products.
Shelley has served on several scientific and development advisory boards for pharmaceutical companies and is on the Scientific Advisory Board for the Consortium for Parasitic Drug Development at the University of North Carolina for the Bill and Melinda Gates Foundation. Prior to becoming a consultant, she was employed by Glaxo Wellcome, Inc. where she had international responsibility for the nonclinical strategy, management, development and safety assessment of compounds in full development in a wide range of therapeutic areas. Prior to her position at GW, she was at Merck Research Laboratories and Burroughs Wellcome, Co. where she was study pathologist and toxicology study director on a number of rodent and non-rodent studies. Shelley also participated on international project teams in the development of antiviral, neurological, pulmonary and metabolic drug products. At Burroughs Wellcome, she managed the pathology and toxicology groups. Shelley was Principal Investigator for a NTP Pathology Support Program at Integrated Laboratory Systems where she managed pathology research studies and served as chairperson for NTP Pathology Working Groups. Prior to her experience in industry, she was a Research Assistant Professor in the Department of Pathology at the University of Miami School of Medicine where she was responsible for a research program in metabolic and bone disease and for service support in diagnostic pathology.
Shelley has served on the Membership Committee (2006-2009) of the American College of Toxicology and is also a member of the Society of Toxicology, the NC Society of Toxicology, and Society of Toxicologic Pathologists. She has published and presented on the toxicology and pathology of bone disease, ophthalmology, antiviral and pulmonary drug products.